Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 bởi

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 bởi

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 bởi

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 bởi

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026 bởi

Daily treatment with oral orforglipron, when added to titrated insulin glargine, has been shown to be beneficial in individuals with inadequately controlled type 2 diabetes (T2D) in the phase 3 ACHIEVE-5 trial.

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026

Tirzepatide superior to ICC in metformin-resistant T2D

17 Jun 2026

Treatment with tirzepatide yields robust reductions in HbA1c, weight, and waist circumference in patients with early type 2 diabetes (T2D) uncontrolled with metformin, reports a study.

Tirzepatide superior to ICC in metformin-resistant T2D

17 Jun 2026

Weight, income status modify impact of extreme temperature events on daily step counts

14 Jun 2026

Individuals with low income or high BMI appear to be more vulnerable to heatwaves, while those with low income or normal BMI tend to have greater sensitivity during cold spells, both of which contribute to fewer daily step counts, suggests a study.

Weight, income status modify impact of extreme temperature events on daily step counts

14 Jun 2026

Trẻ sinh ra trong đại dịch có nguy cơ mắc các bệnh lý liên quan đến bệnh dị ứng do cơ địa cao hơn 46%

10 Jun 2026

Tỷ lệ mắc các bệnh dị ứng cơ địa ở trẻ nhỏ sinh tại Hồng Kông đã tăng 46% trong đại dịch COVID-19, có thể liên quan đến sự thay đổi của hệ vi sinh đường ruột ở trẻ sơ sinh do việc khử trùng mạnh mẽ. SIM03 và SIM05, các công thức sữa chứa lợi khuẩn được phát triển với sự hỗ trợ của trí tuệ nhân tạo (AI), đã chứng minh làm giảm mức độ nặng của chàm và cải thiện chất lượng sống (QoL) ở trẻ em và người lớn, bằng cách điều hòa hệ vi sinh đường ruột.

Trẻ sinh ra trong đại dịch có nguy cơ mắc các bệnh lý liên quan đến bệnh dị ứng do cơ địa cao hơn 46%

10 Jun 2026

Rapid response to obesity medications tied to greater weight loss

09 Jun 2026 bởi

A post hoc analysis of the SURMOUNT-5 study reveals more tirzepatide-treated individuals with obesity achieving all body weight (BW) reduction thresholds than semaglutide-treated participants, with rapid responders showing a greater magnitude of weight loss.

Rapid response to obesity medications tied to greater weight loss

09 Jun 2026

Glycaemic control in T2D better with CGM vs self-monitoring

08 Jun 2026 bởi

In adult patients with type 2 diabetes (T2D) receiving basal insulin alongside other glucose-lowering medications, real-time continuous glucose monitoring (CGM) demonstrates superiority over self-monitoring of blood glucose (SMBG) in terms of optimizing glycaemic control, according to the FreeDM2 study.

Glycaemic control in T2D better with CGM vs self-monitoring

08 Jun 2026

Tin tức & Cập nhật

Xem bài viết Nội tiết

Xem

Chuyên ngành:

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Mazdutide cuts weight in adults with obesity, T2D

Mazdutide cuts weight in adults with obesity, T2D

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

Tirzepatide superior to ICC in metformin-resistant T2D

Tirzepatide superior to ICC in metformin-resistant T2D

Weight, income status modify impact of extreme temperature events on daily step counts

Weight, income status modify impact of extreme temperature events on daily step counts

Trẻ sinh ra trong đại dịch có nguy cơ mắc các bệnh lý liên quan đến bệnh dị ứng do cơ địa cao hơn 46%

Trẻ sinh ra trong đại dịch có nguy cơ mắc các bệnh lý liên quan đến bệnh dị ứng do cơ địa cao hơn 46%

Rapid response to obesity medications tied to greater weight loss

Rapid response to obesity medications tied to greater weight loss

Glycaemic control in T2D better with CGM vs self-monitoring

Glycaemic control in T2D better with CGM vs self-monitoring